SMALL LYMPHOCYTIC LYMPHOMA
Clinical trials for SMALL LYMPHOCYTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SMALL LYMPHOCYTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for SMALL LYMPHOCYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shrinks tumors in hard-to-treat blood cancers
Disease control CompletedThis study tested a drug called acalabrutinib in 48 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had a high-risk genetic change (deletion 17p). The goal was to see how well the drug shrank tumors. Results showed that many patients had a p…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New drug cocktail shows promise in halting leukemia progression
Disease control CompletedThis study tested a combination of drugs (ofatumumab, methylprednisolone, and lenalidomide) in 45 people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal was to see if the treatment could make all signs of cancer disappear or shrink significantl…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New drug combo shows promise for untreated leukemia patients
Disease control CompletedThis study tested a combination of two drugs, idelalisib and ofatumumab, in 27 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not received prior treatment. The goal was to see how well the drugs worked together to shrink or control the …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
New pill shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis study tested an experimental pill called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Promising early results for Two-Drug combo in blood cancer patients
Disease control CompletedThis early-phase study tested a combination of two drugs, acalabrutinib and obinutuzumab, in 69 people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal was to see if the combination was safe and could shrink or eliminate cancer. Participants included tho…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Early drug combo shows promise for high-risk leukemia patients
Disease control CompletedThis study tested whether the drug ibrutinib, given with vaccines, can help people with early-stage but high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer without their cancer getting worse. The trial included 42 participants who had not …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Jennifer Woyach • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Triple attack on lymphoma: freeze, vaccinate, and boost immunity
Disease control CompletedThis study tested a new combination treatment for people with non-Hodgkin lymphoma that had come back. The approach used three steps: first, freezing the tumor to kill cancer cells; second, injecting a personalized vaccine made from the patient's own immune cells; and third, givi…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New cancer drug combo shows promise but doses remain uncertain
Disease control CompletedThis study tested a new drug (BGB-10188) alone or with other drugs in 97 people with certain blood cancers or advanced solid tumors. The goal was to find the safest and most effective dose. However, the best dose could not be determined for all groups because not enough data was …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug combo may reduce transplant complications in blood cancer patients
Disease control CompletedThis study tested different combinations of immune-suppressing drugs to prevent graft-versus-host disease (GVHD) in 174 patients with blood cancers who received a stem cell transplant from an unrelated donor. The goal was to find the most effective approach to reduce severe GVHD,…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
Experimental cell therapy shows promise in Hard-to-Treat blood cancers
Disease control CompletedThis early-phase study tested a new cell therapy called IOV-2001 in 7 patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that had stopped responding to standard treatments. The therapy uses a patient's own immune cells to fight the cancer. The main goals wer…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC